Johnson & Johnson CEO Alex Gorsky told analysts on Tuesday that 2017 was a transition year for its medical device business, but 2018 should be a growth year.
News & Features
The weight-loss balloon maker pulled the plug on a $35 million stock sale after a whistleblower made allegations of improper revenue recognition during the company's fourth quarter.
To kick off earnings season, one medtech analyst thinks the cardiovascular, orthopedic, and diagnostic markets grew last quarter, based on early earnings announcements.
The new startup, called Qrativ, combines Mayo Clinic's clinical expertise with artificial intelligence technology to discover treatments for the untreatable.
U.S. lawmakers reached a deal Monday to end a government shutdown, but the bill also contained an unexpected victory for medtech: another two-year suspension of the medical device tax.
Medical device makers identify risks as part of the product development process, but that information is not typically shared with customers. Should it be?
A molecular diagnostics company wants to expand its new cartridge-based platform to help orthopedic surgeons make more informed care decisions for patients with a potential joint infection.
Obalon Therapeutics, developer of the first FDA-approved swallowable, gas-filled balloon for obesity treatment, is preparing an underwritten public offering of its common stock.
The IRS and the U.S. Treasury Department have decided to give medical device companies relief from failure to deposit penalties for the first three quarters of 2018.
Scientists in Australia have developed an ingestible sensor to detect and measure gut gasses in the stomach. The data can be sent to a phone or computer and could change the way gut disorders are diagnosed and treated.
FDA and Zoll Medical are warning LifeVest 4000 patients to have the device replaced immediately if a specific error message appears on the screen of the wearable defibrillator.
The company recently prevailed in two separate legal battles; one involved a whistleblower lawsuit, and the other was over attorney fees from an old patent case.